Related Experiment Video

Updated: Mar 23, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K

Tanshinone IIA enhances chemosensitivity of colon cancer cells by suppressing nuclear factor-κB

Yangqiu Bai1, Lida Zhang1, Xinhui Fang1

  • 1Department of Gastroenterology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, Henan 450003, P.R. China.

Experimental and Therapeutic Medicine
|March 22, 2016
PubMed

Insights

Tanshinone IIA (TSA) reduces colon cancer cell viability and enhances chemotherapy effectiveness. It works by inhibiting nuclear factor-kappa B (NF-κB) signaling, leading to cancer cell death.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Colon cancer remains a significant global health challenge.
  • Targeted therapies offer potential for improved treatment outcomes.
  • Understanding molecular mechanisms is crucial for developing effective anti-cancer strategies.

Purpose of the Study:

  • To investigate the anti-cancer effects of tanshinone IIA (TSA) on colon cancer cells.
  • To elucidate the molecular mechanism underlying TSA's action, focusing on NF-κB signaling.
  • To evaluate TSA's potential in sensitizing colon cancer cells to chemotherapy.

Main Methods:

  • Cell viability was assessed using the Cell Counting kit-8 assay.
  • Western blotting was employed to analyze protein expression, including phosphorylated p65 and NF-κB-regulated genes (VEGF, c-Myc, COX-2, Bcl-2).
  • The role of NF-κB was further confirmed using a specific inhibitor, pyrrolidine dithiocarbamate.

Main Results:

  • TSA significantly reduced the viability of HCT1116 and COLO205 colon cancer cells in a dose-dependent manner.
  • TSA demonstrated a concentration-dependent chemosensitization effect when combined with fluorouracil.
  • TSA treatment inhibited NF-κB activation by decreasing nuclear phosphorylated p65 and downregulating key target genes (VEGF, c-Myc, COX-2, Bcl-2).

Conclusions:

  • Tanshinone IIA induces apoptosis and enhances chemosensitivity in colon cancer cells.
  • The anti-cancer effects of TSA are mediated through the suppression of the NF-κB signaling pathway.
  • TSA represents a promising therapeutic agent for colon cancer treatment, potentially in combination with chemotherapy.
Keywords:
cell deathchemosensitizationcolon cancernuclear factor-κBtanshinone IIA

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.3K

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
735
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66